Tirzepatide (15mg)

Tirzepatide (15mg)

$129.99
$129.99
SAVE Sold out

✔ Verified 99+% Purity

✔ Third-Party Approved & Tested

✔ Fast Australian Shipping

Research Use Only

This product is sold for research purposes only. It is not intended for human or animal consumption. By purchasing this product, you confirm that you are a qualified researcher or are purchasing for legitimate research purposes.

Bacteriostatic Water (20mg)
Add Bacteriostatic Water (20mg)
Required for reconstitution
$24.99
Tirzepatide (15mg)

Tirzepatide (15mg)

$129.99
$129.99
SAVE Sold out

Shipping Information

Orders are processed and dispatched within 24 hours of payment confirmation (Monday–Friday). Delivery typically arrives within 1–4 business days via Standard post, and 1-2 business days via Express post.

View full details

Tirzepatide

Supplied as a lyophilized (freeze-dried) white powder in a sealed sterile vial. Requires reconstitution with bacteriostatic water prior to use. Each vial contains 15mg of Tirzepatide at ≥99% purity.

Tirzepatide is a dual incretin agonist that activates both GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptors. Where semaglutide acts on GLP-1 alone, Tirzepatide's dual activity is associated with stronger outcomes in clinical research: Phase 3 SURMOUNT trials reported mean body weight reductions of up to 22.5% over 72 weeks — one of the largest figures documented in weight-management research. Tirzepatide established the dual-agonist benchmark now used to evaluate newer tri-agonist compounds such as retatrutide.

Research Background

GLP-1 activation modulates appetite and gastric emptying, while GIP activation modulates insulin sensitivity and fat metabolism; the combined signal is studied for appetite reduction, glycaemic control, and preferential fat-mass reduction. Mechanistically, Tirzepatide mimics hormones that regulate blood sugar, increases insulin secretion, slows gastric emptying, and reduces appetite — a combination studied for its effects on glycaemic control and weight regulation. Research has also extended to cardiometabolic markers such as blood pressure and cholesterol, and to emerging research areas including hepatic steatosis and NASH-related models.

Key Research Areas
Fat loss research — up to 22.5% body weight reduction over 72 weeks in Phase 3 trials
Appetite regulation — studied for reduced food intake via gastric emptying and central appetite signalling
Glycaemic control — studied for insulin sensitivity and HbA1c reduction in type 2 diabetes research
Body composition — studied for preferential fat-mass reduction over lean mass
Cardiometabolic markers — studied for blood pressure, cholesterol, and cardiovascular risk improvements
Hepatic steatosis — emerging research on fatty liver markers and NASH-related models
Studied Mechanisms
Dual agonism at GLP-1 and GIP receptors
Fatty-acid conjugation supporting extended half-life
Glucose-dependent insulin secretion and increased insulin sensitivity
Slowed gastric emptying and central appetite suppression
Comparative benchmark for evaluating newer tri-agonist compounds

Product Specifications

Molecular FormulaC₂₂₅H₃₄₈N₄₈O₆₈
Molecular Weight4,813.5 g/mol
CAS Number2023788-19-2
Sequence39 amino acid peptide on a GIP receptor backbone, conjugated to a C20 fatty diacid moiety for extended half-life
AppearanceLyophilised Powder
Purity≥99% (HPLC Verified)
StorageStore at -20°C, away from light and moisture
Research Use Only

This product is strictly intended for in vitro laboratory research purposes only. It is not approved for human or veterinary use, and is not intended for consumption, injection, or any therapeutic application.